Mogy Joel R Investment Counsel Has Lifted Its Facebook (FB) Position; 6 Analysts Covering Synergy Pharmaceuticals Inc. (SGYP)

January 21, 2018 - By Louis Casey

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 35 analyst reports since August 25, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of SGYP in report on Friday, September 8 with “Buy” rating. H.C. Wainwright maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) rating on Monday, June 12. H.C. Wainwright has “Buy” rating and $1800 target. Citigroup downgraded the shares of SGYP in report on Friday, December 18 to “Neutral” rating. Rodman & Renshaw maintained the shares of SGYP in report on Monday, May 9 with “Buy” rating. The rating was initiated by BTIG Research with “Buy” on Tuesday, August 25. The rating was maintained by Cantor Fitzgerald on Wednesday, September 27 with “Buy”. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, June 7. The rating was maintained by Citigroup with “Neutral” on Wednesday, March 16. Rodman & Renshaw maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) rating on Friday, January 20. Rodman & Renshaw has “Buy” rating and $18 target. The firm has “Buy” rating given on Thursday, October 29 by TH Capital. See Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) latest ratings:

08/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0 Maintain
05/01/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Perform Old Target: $10 Downgrade
04/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $7.0 Maintain
21/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $10.0 Maintain
10/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $13.0 Maintain
09/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $10.0 Maintain
18/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $8.0 Maintain
11/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $8.0 Maintain
10/10/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0 Maintain
27/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $11.0 Maintain

Mogy Joel R Investment Counsel Inc increased Facebook Inc (FB) stake by 3.28% reported in 2017Q3 SEC filing. Mogy Joel R Investment Counsel Inc acquired 2,865 shares as Facebook Inc (FB)’s stock rose 10.88%. The Mogy Joel R Investment Counsel Inc holds 90,295 shares with $15.43M value, up from 87,430 last quarter. Facebook Inc now has $526.79B valuation. The stock increased 0.83% or $1.49 during the last trading session, reaching $181.29. About 26.83M shares traded or 48.59% up from the average. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since January 21, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Investors sentiment increased to 1.9 in 2017 Q3. Its up 0.41, from 1.49 in 2017Q2. It increased, as 16 investors sold Synergy Pharmaceuticals Inc. shares while 23 reduced holdings. 21 funds opened positions while 53 raised stakes. 147.06 million shares or 7.33% less from 158.68 million shares in 2017Q2 were reported. Exane Derivatives holds 0.03% or 60,205 shares. Trellus Mngmt has invested 1.44% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Moreover, Tiaa Cref Invest Mngmt Lc has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 1.23 million shares. Edge Wealth Limited Liability Co has 50 shares for 0% of their portfolio. Bancorp Of Montreal Can has 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 115,511 shares. Benjamin F Edwards Communications has invested 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Parallax Volatility Advisers Ltd Partnership has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Moreover, Knott David M has 0.2% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 158,400 shares. Victory Capital Mngmt holds 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) or 5,015 shares. Barclays Public Limited holds 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 29,666 shares. Teacher Retirement Of Texas owns 18,370 shares for 0% of their portfolio. Williams Jones Ltd Liability Co reported 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Nationwide Fund stated it has 329,353 shares or 0% of all its holdings. Tower Research Cap Ltd Liability (Trc) reported 1,632 shares. Clear Harbor Asset Management Ltd Limited Liability Company invested 0.17% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP).

The stock increased 5.73% or $0.13 during the last trading session, reaching $2.4. About 5.41M shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since January 21, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. The company has market cap of $591.98 million. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. It currently has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

Since August 7, 2017, it had 0 insider buys, and 1 insider sale for $98,972 activity. $98,972 worth of stock was sold by PAULSON & CO. INC. on Monday, August 7.

Among 53 analysts covering Facebook (NASDAQ:FB), 49 have Buy rating, 2 Sell and 2 Hold. Therefore 92% are positive. Facebook had 220 analyst reports since July 21, 2015 according to SRatingsIntel. Needham maintained the shares of FB in report on Wednesday, July 19 with “Buy” rating. KeyBanc Capital Markets maintained the stock with “Overweight” rating in Thursday, November 2 report. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, August 27. Deutsche Bank maintained the stock with “Buy” rating in Thursday, November 2 report. RBC Capital Markets maintained Facebook, Inc. (NASDAQ:FB) on Thursday, November 5 with “Outperform” rating. The stock has “Buy” rating by KeyBanc Capital Markets on Wednesday, September 6. The firm has “Sell” rating given on Monday, July 31 by Pivotal Research. Piper Jaffray maintained the shares of FB in report on Thursday, January 28 with “Overweight” rating. Canaccord Genuity maintained it with “Buy” rating and $230.0 target in Tuesday, January 2 report. Susquehanna initiated the shares of FB in report on Monday, August 10 with “Positive” rating.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>